Ldl Cholesterol

BOSTON — The medical community is better equipped to combat residual CVD risk than previously, but prevention of residual risk should be tailored using a precision medicine approach, a speaker said at the Cardiometabolic Health Congress.

Long-term safety of evolocumab (Repatha, Amgen) in FOURIER participants.

An LDL target of less than 70 mg/dL with ezetimibe plus statin therapy was associated with lower risk for subsequent events after stroke/transient ischemic attack at 5 years vs. a target between 90 mg/dL and 110 mg/dL, researchers reported.

An expert consensus decision pathway recently issued by the American College of Cardiology addresses lipid-lowering therapies that were developed after the publication of the ACC/American Heart Association cholesterol guidelines in 2018.

In a phase 2 trial, obicetrapib, an investigational cholesteryl ester transfer protein inhibitor, decreased LDL, non-HDL, lipoprotein(a) and apolipoprotein B and increased HDL at 8 weeks, researchers reported in Nature Medicine.

Data from an open-label extension of the FOURIER study show use of the PCSK9 inhibitor evolocumab for more than 7 years led to durable reductions in LDL and a reduction in CV events, including CV death, according to a speaker.

LOUISVILLE, Ky. — Changes in HDL level may be linked with SARS-CoV-2 infection risk and subsequent outcomes in COVID-19, a speaker reported.

Researchers have identified lipid cutoffs that may indicate elevated risk for MI and stroke among young adults aged 20 to 39 years without a history of diabetes, according to findings published in European Journal of Preventive Cardiology.

Among adults with atherosclerotic CVD at very high risk, moderate-intensity statin plus ezetimibe combination therapy was noninferior to high-intensity statin monotherapy for major CV outcomes at 3 years, including CV death, data show.